.: ORİJİNAL ARAŞTIRMA
Serum Prolactin Levels in Adult Females with Telogen Effluvium: A Case Control Study
Erişkin Kadın Telogen Effluvium Hastalarında Serum Prolaktin Düzeyleri: Vaka Kontrol Çalışması
Turkiye Klinikleri J Dermatol. 2021;31(3):174-8
doi: 10.5336/dermato.2021-82848
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: The effect of prolactin hormone on hair follicle is complicated and the relationship between prolactin and hair loss is still controversial. The aim of this study is to evaluate the serum prolactin levels in female patients with telogen effluvium and to discuss its role in hair loss. Material and Methods: Forty-seven adult female patients diagnosed with telogen effluvium and forty-two age matched healthy female controls were included in this retrospective study. Serum prolactin levels were statistically compared between telogen effluvium patients and healthy controls (Mann-Whitney U test). Results: The median age of patient group was 29 (19-46) years and the median duration of symptoms was 12 (1-156) months. Neither patients nor the controls had hyperprolactinemia. The median serum prolactin level of patients was 10.47 ng/mL (2.75-23.53) which is statistically significantly lower than controls (p=0.033). No statistically significant difference was detected in prolactin levels between acute and chronic telogen effluvium patients (p=0.444). Conclusion: In contrast to most studies mentioning the catagen inducing effect of prolactin, in this study lower prolactin levels were found in patients diagnosed with telogen effluvium compared to the control group. However the majority of these studies associating hyperprolactinemia and hair loss include hyperandrogenemic cases and the catagen inducing effect of prolactin is mostly reported with high doses. In this study, absence of patients with hyperprolactinemia and hyperandrogenism may explain the contrast findings with the literature. As a result, it may be useful to consider the dose and gender dependent effects of prolactin in hair loss.
Keywords: Prolactin; alopecia; hair loss
Objective: The effect of prolactin hormone on hair follicle is complicated and the relationship between prolactin and hair loss is still controversial. The aim of this study is to evaluate the serum prolactin levels in female patients with telogen effluvium and to discuss its role in hair loss. Material and Methods: Forty-seven adult female patients diagnosed with telogen effluvium and forty-two age matched healthy female controls were included in this retrospective study. Serum prolactin levels were statistically compared between telogen effluvium patients and healthy controls (Mann-Whitney U test). Results: The median age of patient group was 29 (19-46) years and the median duration of symptoms was 12 (1-156) months. Neither patients nor the controls had hyperprolactinemia. The median serum prolactin level of patients was 10.47 ng/mL (2.75-23.53) which is statistically significantly lower than controls (p=0.033). No statistically significant difference was detected in prolactin levels between acute and chronic telogen effluvium patients (p=0.444). Conclusion: In contrast to most studies mentioning the catagen inducing effect of prolactin, in this study lower prolactin levels were found in patients diagnosed with telogen effluvium compared to the control group. However the majority of these studies associating hyperprolactinemia and hair loss include hyperandrogenemic cases and the catagen inducing effect of prolactin is mostly reported with high doses. In this study, absence of patients with hyperprolactinemia and hyperandrogenism may explain the contrast findings with the literature. As a result, it may be useful to consider the dose and gender dependent effects of prolactin in hair loss.
Keywords: Prolactin; alopecia; hair loss
ÖZET
Amaç: Prolaktin hormonunun saç folikülü üzerindeki etkisi karmaşıktır ve saç dökülmesi ile ilişkisi hala tartışmalıdır. Bu çalışmanın amacı, telogen effluvium tanısı alan kadın hastalarda serum prolaktin düzeylerini değerlendirmek ve saç dökülmesindeki rolünü tartışmaktır. Gereç ve Yöntemler: Bu retrospektif çalışmaya telogen effluvium tanısı almış 47 yetişkin kadın hasta ve yaş uyumlu 42 kadın sağlıklı kontrol dahil edildi. Serum prolaktin düzeyleri telogen effluvium hastaları ve sağlıklı kontrol grubu arasında istatistiksel olarak karşılaştırıldı (Mann-Whitney U testi). Bulgular: Hasta grubunun ortanca yaşı 29 (19-46) ve ortanca semptom süresi 12 (1-156) aydı. Hasta ve kontrol grubunda hiperprolaktinemi yoktu. Hasta grubunun ortanca serum prolaktin düzeyi 10,47 ng / mL (2,75-23,53) olup, kontrol grubuna göre istatistiksel olarak anlamlı derecede düşüktü (p=0,033). Akut ve kronik telogen effluvium hastaları arasında prolaktin düzeylerinde istatistiksel olarak anlamlı fark saptanmadı (p=0,444). Sonuç: Prolaktinin katajen indükleyici etkisinden bahseden çoğu çalışmanın aksine, bu çalışmada telogen effluvium tanısı alan hastalarda kontrol grubuna göre daha düşük prolaktin seviyeleri bulunmuştur. Bununla birlikte, hiperprolaktinemi ve saç dökülmesini ilişkilendiren bu çalışmaların çoğu hiperandrojenemik vakaları içermektedir ve prolaktinin katajen indükleyici etkisi çoğunlukla yüksek dozlarda bildirilmektedir. Bu çalışmada hiperprolaktinemi ve hiperandrojenizmi olan hastaların yokluğu literatürle kontrast bulgularını açıklayabilir. Sonuç olarak saç dökülmesinde prolaktinin doz ve cinsiyete bağlı etkilerinin dikkate alınması faydalı olabilir.
Anahtar Kelimeler: Prolaktin; alopesi; saç dökülmesi
Amaç: Prolaktin hormonunun saç folikülü üzerindeki etkisi karmaşıktır ve saç dökülmesi ile ilişkisi hala tartışmalıdır. Bu çalışmanın amacı, telogen effluvium tanısı alan kadın hastalarda serum prolaktin düzeylerini değerlendirmek ve saç dökülmesindeki rolünü tartışmaktır. Gereç ve Yöntemler: Bu retrospektif çalışmaya telogen effluvium tanısı almış 47 yetişkin kadın hasta ve yaş uyumlu 42 kadın sağlıklı kontrol dahil edildi. Serum prolaktin düzeyleri telogen effluvium hastaları ve sağlıklı kontrol grubu arasında istatistiksel olarak karşılaştırıldı (Mann-Whitney U testi). Bulgular: Hasta grubunun ortanca yaşı 29 (19-46) ve ortanca semptom süresi 12 (1-156) aydı. Hasta ve kontrol grubunda hiperprolaktinemi yoktu. Hasta grubunun ortanca serum prolaktin düzeyi 10,47 ng / mL (2,75-23,53) olup, kontrol grubuna göre istatistiksel olarak anlamlı derecede düşüktü (p=0,033). Akut ve kronik telogen effluvium hastaları arasında prolaktin düzeylerinde istatistiksel olarak anlamlı fark saptanmadı (p=0,444). Sonuç: Prolaktinin katajen indükleyici etkisinden bahseden çoğu çalışmanın aksine, bu çalışmada telogen effluvium tanısı alan hastalarda kontrol grubuna göre daha düşük prolaktin seviyeleri bulunmuştur. Bununla birlikte, hiperprolaktinemi ve saç dökülmesini ilişkilendiren bu çalışmaların çoğu hiperandrojenemik vakaları içermektedir ve prolaktinin katajen indükleyici etkisi çoğunlukla yüksek dozlarda bildirilmektedir. Bu çalışmada hiperprolaktinemi ve hiperandrojenizmi olan hastaların yokluğu literatürle kontrast bulgularını açıklayabilir. Sonuç olarak saç dökülmesinde prolaktinin doz ve cinsiyete bağlı etkilerinin dikkate alınması faydalı olabilir.
Anahtar Kelimeler: Prolaktin; alopesi; saç dökülmesi
REFERANSLAR:
- Foitzik K, Krause K, Conrad F, Nakamura M, Funk W, Paus R. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol. 2006;168(3):748-56. [Crossref] [PubMed] [PMC]
- Foitzik K, Langan EA, Paus R. Prolactin and the skin: a dermatological perspective on an ancient pleiotropic peptide hormone. J Invest Dermatol. 2009;129(5):1071-87. [Crossref] [PubMed]
- Sackmann-Sala L, Guidotti JE, Goffin V. Minireview: prolactin regulation of adult stem cells. Mol Endocrinol. 2015;29(5):667-81. [Crossref] [PubMed] [PMC]
- Lutz G. Hair loss and hyperprolactinemia in women. Dermatoendocrinol. 2012;4(1):65-71. doi: 10.4161/derm.19472. [Crossref] [PubMed] [PMC]
- Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988;19(5 Pt 1):831-6. [Crossref] [PubMed]
- Shrivastava SB. Diffuse hair loss in an adult female: approach to diagnosis and management. Indian J Dermatol Venereol Leprol. 2009;75(1):20-7; quiz 27-8. [Crossref] [PubMed]
- Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015;9(9):WE01-3. [PubMed] [PMC]
- McDonald KA, Shelley AJ, Colantonio S, Beecker J. Hair pull test: Evidence-based update and revision of guidelines. J Am Acad Dermatol. 2017;76(3):472-7. Epub 2016 Dec 20. [Crossref] [PubMed]
- Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen effluvium: a review of the literature. Cureus. 2020;12(5):e8320. [Crossref] [PubMed] [PMC]
- Ramot Y, Bíró T, Tiede S, Tóth BI, Langan EA, Sugawara K, et al. Prolactin--a novel neuroendocrine regulator of human keratin expression in situ. FASEB J. 2010;24(6):1768-79. [Crossref] [PubMed]
- Langan EA, Vidali S, Pigat N, Funk W, Lisztes E, Bíró T, et al. Tumour necrosis factor alpha, interferon gamma and substance P are novel modulators of extrapituitary prolactin expression in human skin. PLoS One. 2013;8(4):e60819. [Crossref] [PubMed] [PMC]
- Pearson AJ, Parry AL, Ashby MG, Choy VJ, Wildermoth JE, Craven AJ. Inhibitory effect of increased photoperiod on wool follicle growth. J Endocrinol. 1996;148(1):157-66. [Crossref] [PubMed]
- Puchala R, Pierzynowski SG, Wuliji T, Goetsch AL, Soto-Navarro SA, Sahlu T. Effects of prolactin administered to a perfused area of the skin of Angora goats. J Anim Sci. 2003;81(1):279-84. [Crossref] [PubMed]
- Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001;81(1):449-94. [Crossref] [PubMed]
- Foitzik K, Krause K, Nixon AJ, Ford CA, Ohnemus U, Pearson AJ, et al. Prolactin and its receptor are expressed in murine hair follicle epithelium, show hair cycle-dependent expression, and induce catagen. Am J Pathol. 2003;162(5):1611-21. [Crossref] [PubMed] [PMC]
- Craven AJ, Nixon AJ, Ashby MG, Ormandy CJ, Blazek K, Wilkins RJ, et al. Prolactin delays hair regrowth in mice. J Endocrinol. 2006;191(2):415-25. [Crossref] [PubMed]
- Schmidt JB. Hormonal basis of male and female androgenic alopecia: clinical relevance. Skin Pharmacol. 1994;7(1-2):61-6. [Crossref] [PubMed]
- Orfanos CE, Hertel H. Haarwachstumsstörung bei Hyperprolaktinämie [Disorder of hair growth in hyperprolactinemia]. Z Hautkr. 1988;63(1):23-6. German. [PubMed]
- Schmidt JB, Schurz B, Huber J, Spona J. Hypothyreose und Hyperprolaktinämie als mögliche Ursache der androgenetischen Alopezie der Frau [Hypothyroidism and hyperprolactinemia as a possible cause of androgenetic alopecia in the female]. Z Hautkr. 1989;64(1):9-12. German. [PubMed]
- Carmina E, Stanczyk F, Lobo RA. Evaluation of hormonal status. In: Strauss J, Barbieri R, Gargiulo A, eds. Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. 8th ed. Philadelphia, PA: Elsevier; 2019. p.887-915. [Crossref]
- Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Clin Endocrinol Metab. 2019;104(7):2875-91. [Crossref] [PubMed]
- Girolomoni G, Phillips JT, Bergstresser PR. Prolactin stimulates proliferation of cultured human keratinocytes. J Invest Dermatol. 1993;101(3):275-9. [Crossref] [PubMed]
- Langan EA, Ramot Y, Goffin V, Griffiths CE, Foitzik K, Paus R. Mind the (gender) gap: does prolactin exert gender and/or site-specific effects on the human hair follicle? J Invest Dermatol. 2010;130(3):886-91. [Crossref] [PubMed]
- Katz KA, Cotsarelis G, Gupta R, Seykora JT. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease. J Am Acad Dermatol. 2006;55(5 Suppl):S103-4. [Crossref] [PubMed]
- Fabre N, Montastruc JL, Rascol O. Alopecia: an adverse effect of bromocriptine. Clin Neuropharmacol. 1993;16(3):266-8. [Crossref] [PubMed]
- Blum I, Leiba S. Increased hair loss as a side effect of bromocriptine treatment. N Engl J Med. 1980;303(24):1418. [Crossref] [PubMed]
- Stárka L, Cermáková I, Dusková M, Hill M, Dolezal M, Polácek V. Hormonal profile of men with premature balding. Exp Clin Endocrinol Diabetes. 2004;112(1):24-8. [Crossref] [PubMed]
- Farland LV, Mu F, Eliassen AH, Hankinson SE, Tworoger SS, Barbieri RL, et al. Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. Cancer Causes Control. 2017;28(12):1441-52. [Crossref] [PubMed] [PMC]
.: İşlem Listesi